Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2).

Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ. · 2005

Read Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). by Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ. (2005) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8062222.txt.

Introduction

Lambert and co-authors pin down the enzyme that sheds the SARS virus receptor from cell surfaces. ACE2 guards heart function and serves as the door for SARS-CoV. A soluble form of ACE2 can block the virus from binding. The team asked how that soluble form gets cut loose. They worked with ACE2 in both engineered and natural cell lines.

ACE2 underwent shedding driven by a metalloproteinase, triggered by phorbol ester. Inhibitor tests pointed at ADAM17 as the cutter. Silencing ADAM17 with small interfering RNA cut the shedding down. Adding extra ADAM17 raised it sharply instead. The authors name ADAM17 as the agent of this regulated release. The finding may clarify what ACE2 does in the body. It also hints at levers over the virus's own receptor.

Catalog record

CREATORLambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ.
YEAR2005
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8062222

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Tumor Necrosis Factor-α Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2)* By Daniel W. Lambert, Mike Yarski, Fiona J. Warner, Paul Thornhill, Edward T. Parkin, A. Ian Smith, Nigel M. Hooper, Anthony J. Turner Published in: The Journal of Biological Chemistry DOI: 10.1074/jbc.M505111200 ABSTRACT Angiotensin-converting enzyme-2 (ACE2) is a critical regulator of heart function and a cellular receptor for the causative agent of severe-acute respiratory syndrome (SARS), SARS-CoV (coronavirus). ACE2 is a type I transmembrane protein, with an extracellular N-terminal domain containing the active site and a short intracellular C-terminal tail. A soluble form of ACE2, lacking its cytosolic and transmembrane domains, has been shown to block binding of the SARS-CoV spike protein to its receptor. In this study, we examined the ability of ACE2 to undergo proteolytic shedding and investigated the mechanisms responsible for this shedding event. We demonstrated that ACE2, heterologously expressed in HEK293 cells and endogenously expressed in Huh7 cells, undergoes metalloproteinase-mediated, phorbol ester-inducible ectodomain shedding. By using inhibitors with differing potency toward different members of the ADAM (adisintegrin and metalloproteinase) family of proteases, we identified ADAM17 as a candidate mediator of stimulated ACE2 shedding. Furthermore, ablation of ADAM17 expression using specific small interfering RNA duplexes reduced regulated ACE2 shedding, whereas overexpression of ADAM17 significantly increased shedding. Taken together, these data provided direct evidence for the involvement of ADAM17 in the regulated ectodomain shedding of ACE2. The identification of ADAM17 as the protease responsible for ACE2 shedding may provide new insight into the physiological roles of ACE2. Angiotensin-converting enzyme-2 (ACE2)1 is the only known mammalian homologue of the zinc-metallopeptidase angiotensin-converting enzyme (ACE), a critical regulator of the reninangiotensin system (1, 2). Unlike ACE, which functions as a peptidyl dipeptidase, ACE2 acts as a carboxypeptidase, able to cleave a single C-terminal residue from a number of physiologically significant peptides (3, 4). Although the precise physiological role of ACE2 remains to be identified, studies in vivo have revealed that ACE2 is an essential regulator of heart function (5). ACE2 is also thought to have an important regulatory role in the renin-angiotensin system through its ability to convert the potent vasoconstrictor angiotensin II to the vasodilatory peptide angiotensin-1-7 (6). In addition, ACE2 has been recently identified as a functional receptor for the causative agent of severe-acute respiratory syndrome (SARS), the SARS coronavirus (7, 8). ACE2 is an 805-amino-acid glycoprotein with an apparent molecular mass of 120 kDa (3, 9). Like ACE, ACE2 is a type I transmembrane protein comprising a short C-terminal cytoplasmic tail, a hydrophobic transmembrane region, and a heavily N-glycosylated N-terminal ectodomain containing the active site (3). ACE2 has a more restricted tissue distribution than ACE, being found predominantly in the heart, kidneys, and testes (3, 4), although low levels have been detected in a variety of tissues (10). It is becoming increasingly apparent that the proteolytic shedding of cell surface proteins is an important mechanism regulating their expression and function. This ectodomain shedding event has been observed for a variety of membrane proteins with distinct functions, including cytokines (tumor necrosis factor-α (TNF-α), fractalkine), enzymes (ACE, β-site amyloid cleaving enzyme (BACE)), adhesion molecules (L-selectin), and proteins associated with neuropathological disorders (amyloid precursor protein (APP), cellular prion protein) (11, 12, 13, 14, 15, 16, 17). Although many of these proteins are shed in vitro under normal cell culture conditions, shedding is often stimulated by phorbol esters such as PMA (phorbol-12-myristate-13-acetate) and a number of other factors (18, 19). Both constitutive and PMA-stimulated ectodomain shedding appear to be mediated largely by members of the ADAM family (a disintegrin and metalloproteinase) of zinc-metalloproteinases (reviewed in Ref. 20). The best characterized ADAM protease to date is ADAM17, or TNF-α-converting enzyme, which was first identified as the sheddase for TNF-α but has subsequently been implicated in the shedding of other cell surface proteins (21, 22, 23). Other members of the ADAM family of proteinases, particularly ADAM9, ADAM10, and ADAM12, have been implicated as candidate sheddases for a wide range of proteins including APP, CXCL16, and heparin-binding epidermal growth factor (24, 25, 26, 27). In this study, we have sought to determine whether ACE2 undergoes proteolytic cleavage resulting in the release of its ectodomain. We provided evidence that a catalytically active soluble form of ACE2 is cleaved from the membrane by two distinct mechanisms: a low level constitutive shedding and a regulated shedding stimulated by phorbol ester. We further used a variety of strategies to establish that ADAM17 is responsible for the regulated shedding of ACE2. The implications of these findings for the role of ACE2 in vivo are also discussed. MATERIALS AND METHODS PMA and all other routinely used reagents were purchased from Sigma unless otherwise stated. The hydroxamate-based inhibitors TAPI-1 and GM6001 were purchased from Calbiochem and Chemicon, respectively. The ADAM-specific inhibitors GW280264X ((2R,3S)-3-(formyl-hydroxyamino)-2-(2-methyl-1-propyl) hexanoic acid ((1S)-5-benzyloxycarbamoylamino-1-(1,3-thiazol-2-ylcarbamoyl)-1-pentyl) amide) and GI254023X ((2R,3S)-3-(formyl-hydroxyamino)-2-(3-phenyl-1-propyl) butanoic acid ((1S)-2,2-dimethyl-1-methylcarbamoyl-1-propyl) amide) (12, 14) were kindly provided by Dr. I. Hussain (GlaxoSmithKline, Harlow, UK). The purified N-terminal domains of TIMP-1 and TIMP-3 were a gift of Prof. H. Nagase (Imperial College, London). Antibodies raised to C-terminal ACE2 peptide sequences were obtained from Pepceuticals and Santa Cruz Biotechnology. Additionally, a polyclonal antibody raised to the ectodomain of human ACE2 was obtained from R&D Systems. The ACE2-specific fluorescent substrate Mca-APK(Dnp) was synthesized by Dr. G. Knight (Cambridge University, Cambridge, UK). A polyclonal antibody to human ADAM17 was obtained from Chemicon, a polyclonal antibody to human ADAM10 was obtained from Calbiochem, and a polyclonal antibody to human ADAM9 from Oncogene. A polyclonal antibody to β-actin was purchased from Sigma. Donkey anti-goat and sheep anti-rabbit horseradish peroxidase-conjugated secondary antibodies were purchased from Sigma and Amersham Biosciences, respectively. Genejuice transfection reagent was obtained from Novagen, and Lipofectamine and Oligofectamine were obtained from Invitrogen. RNA duplexes for siRNA were obtained from Eurogentec or Dharmacon, as indicated. Cell Culture and Transfection—HEK293 cells (kindly provided by Prof. N. Buckley, University of Leeds) and Huh7 cells (kindly provided by Dr. M. Harris, University of Leeds) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum, 2 mm essential amino acids, 100 units/ml penicillin, and 100 μg/ml streptomycin. Stable expression of human ACE2 in HEK293 cells was achieved by transfecting pCI-Neo expression plasmids (Promega) encoding full-length ACE2 and neomycin phosphotransferase (5 μg per transfection; see below for construction details) using Genejuice transfection reagent (Novagen). Recombinant clones were selected using 100 μg/ml gentamycin sulfate (G418; PAA Laboratories GmbH), and expression of ACE2 was confirmed by Western blotting. Plasmid Construction—cDNA encoding full-length human ACE2 (GenBank™ accession number AB046569) was amplified from a human kidney cDNA library (Clontech) using the primer pair 5′-ACGTCCATGTCAAGCTCTTCCTGGCTCCTTCTC-3′ (forward) and 5′-CTAGGCTAAAAGGAGGTCTGAACATCATCAGTGTTT-3′ (reverse), digested, and ligated into the XbaI and XhoI sites of the pCI-Neo expression vector (Promega). The sequence fidelity of the insert was confirmed by automated sequencing (Lark Technologies Inc.). Murine ADAM17 in pcDNA3.1 (kindly provided by Immunex Corp.) was reamplified using the forward primer 5′-CGGGATCCACCATGAGGCGGCGTCTCCT-3′ (containing the Kozak sequence) and the reverse primer 5′-CCGCTCGAGGCACTCTGTCTCTTTGCTGTCA-3′. The resulting amplicons were digested with BamHI and XhoI and ligated into the expression vector pcDNA3.1a (BD Biosciences). Murine ADAM9 was amplified using the forward primer 5′-CTGGATCCACCATGGGGCCGCGCGCGCT-3′ and the reverse primer 5′-ATAGTTTAGCGGCCGCGGTGAGGGAGCTATATAAAGGAGGTGC AGGAGCG-3′. The resulting amplicons were digested with

Read the complete text